Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

A smart, hybrid neural-computo device for drug discovery

NEUREKA

NEUREKA will bring a paradigm shift in drug discovery for neurological diseases, a sector that suffers multiple, repeated failures exacerbating the economical and societal burden of these incurable diseases. It will do so by addressing a crucial shortcoming: the lack of in vitro systems faithfully reproducing brain pathology that enable the...
Funding Programme
Start Date
End Date
Total Funding
€ 2 776 705
European Countries Involved

Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy

AETIONOMY

IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and  (II) the focused application of this pipeline to derive clinically...

Funding Programme
Start Date
End Date
Total Funding
€ 17 546 060

Alzheimer Disease - gut connection

AD-gut

Alzheimer’s disease (AD) is the leading cause of dementia in the Western world and to date no cure nor any preventive strategy are available for this neurodegenerative disorder. Bacterial 16S rRNA sequencing from fecal samples revealed a remarkable shift in the gut microbiota of conventionally-raised AD mice compared to healthy, wild-type mice...
Funding Programme
Start Date
End Date
Total Funding
€ 7 686 620
European Countries Involved

Amyloid imaging to Prevent Alzheimer’s Disease

AMYPAD

Beta-amyloid (β-amyloid) deposition is considered to be a necessary - but not sufficient - step on the path towards Alzheimer’s disease (AD). Depiction of brain β-amyloid in vivo can support an early diagnosis, and even provide an opportunity for consider secondary prevention of AD. Currently, however, the value of β-amyloid PET remains elusive...

Funding Programme
Start Date
End Date
Total Funding
€ 27 329 288

An embodied perspective on anosognosia

VirtualSync

In addition to impairments in episodic and spatial memory, a lack of awareness for one’s memory deficits (also referred to as anosognosia) may be considered a crucial cognitive marker of Alzheimer’s Disease (AD). However, although a growing body of interesting models have been proposed to explain this early symptom, what is still missing is a...
Funding Programme
Start Date
End Date
Total Funding
€ 175 420
European Countries Involved

Biomarker based diagnosis of rapid progressive dementias – optimisation of diagnostic protocols.

DEMTEST

DEMTEST has established a large European and global collaboration between national surveillance units and dementia research centres, facilitating cooperation between neurologists, neuropathologists and neuroscientists. We work on standardisation of tests that are currently available and harmonise their use between centers worldwide. We define...
Funding Programme
Start Date
End Date
Total Funding
€ 2 200 000

Biomarkers for Alzheimer’s disease and Parkinson’s disease.

BIOMARKAPD

Neurodegenerative disorders, represented mostly by Alzheimer's disease (AD) and Parkinson's disease (PD), are characterised by progressive neuronal impairment and death. In spite of the brain's known capacity for regeneration, lost neurons generally cannot be replaced. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to...

Funding Programme
Start Date
End Date
Total Funding
€ 449 066

Brain barriers training

BtRAIN

The brain barriers function to protect the central nervous system (CNS) from neurotoxic compounds. By the same traits they unfortunately block delivery of drugs to the CNS thus hindering proper diagnosis and effective treatment of neurological disorders including Alzheimer’s disease and multiple sclerosis. The unusual complexity of the brain...
Funding Programme
Start Date
End Date
Total Funding
€ 3 067 402

Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases

CaSR Biomedicine

The calcium sensing receptor (CaSR) is a class C Gprotein-coupled receptor that plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone secretion and urinary Ca excretion. Abnormal CaSR function is implicated in calciotropic disorders, and in non-calciotropic disorders such as Alzheimer’s disease (AD), cardiovascular...
Funding Programme
Start Date
End Date
Total Funding
€ 3 657 195

CARELINK for People with Dementia and their community

CARE-LINK

The objective of CARELINK is to deliver a tracking solution that addresses the issue of wandering in People with Dementia (PwD), allowing carers to monitor PwD. Using current machine-learning technologies we will profile user routes that can then be used to build a repository of route patterns to be compared against live routes, thus allowing for...

Funding Programme
Start Date
End Date
Total Funding
€ 2 282 944
European Countries Involved

Coaching system for functional exercise training of frail people with dementia

CO-TRAIN

Frailty leads to reduced competence in activities of daily living, independence, as well as secondary health problems and threats, e.g. falls, depression, anxiety and isolation. Frailty in persons with dementia interacts within a “vicious circle”, promoting physical decline. CO-TRAIN will develop a coaching system for functional exercise training...
Funding Programme
Start Date
End Date
Total Funding
€ 2 660 000
European Countries Involved

Common mechanisms and pathways in Stroke and Alzheimer's disease.

CoSTREAM

Common mechanisms and pathways in Stroke and Alzheimer's disease. It has long been recognized that stroke and (Alzheimer’s Disease) AD often co-occur and have an overlapping pathogenesis. As such, these two diseases are not considered fellow travelers, but rather partners in crime. This multidisciplinary consortium includes epidemiologists...
Funding Programme
Start Date
End Date
Total Funding
€ 5 100 373
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).